
    
      This is an open label, single center study designed to provide continued access to PRO 140 to
      a subject who have completed participation in PRO140_CD02 and continue to receive clinical
      benefit.

      The subject will receive weekly PRO 140 SC injection along with oral ART regimen during the
      Treatment Phase. The study treatment (PRO 140 SC injections) will be administered by a
      qualified medical professional or self-administered by the subject.
    
  